- Hepatitis C Virus Inhibitors
-
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- -
-
Page/Page column 139-140
(2008/12/05)
-
- PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN
-
The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
- -
-
Page/Page column 29
(2010/11/28)
-
- HEPATITIS C VIRUS INHIBITORS
-
Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.
- -
-
-
- Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
-
The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
- -
-
-
- Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa.
-
The design, synthesis and SAR of sulfonamidopyrrolidinone fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteasesof interest (>600 fold).
- Choi-Sledeski,Becker,Green,Davis,Ewing,Mason,Ly,Spada,Liang,Cheney,Barton,Chu,Brown,Colussi,Bentley,Leadley,Dunwiddie,Pauls
-
p. 2539 - 2544
(2007/10/03)
-